{"id":3875,"date":"2018-01-23T12:07:11","date_gmt":"2018-01-23T11:07:11","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/"},"modified":"2020-06-26T14:23:50","modified_gmt":"2020-06-26T12:23:50","slug":"nanexa-forstarker-med-advisory-board-inom-onkologi","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","title":{"rendered":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/strong><\/div>\n<p>Nanexa har identifierat onkologiomr\u00e5det som s\u00e4rskilt intressant och siktar p\u00e5 att under f\u00f6rsta halv\u00e5ret 2018 fatta ett inriktningsbeslut f\u00f6r ett eget produktprojekt inom omr\u00e5det. I syfte att staka ut v\u00e4gen f\u00f6r Nanexas egna produktprojekt har Bolaget samlat ett Advisory Board med djupa kunskaper inom onkologiomr\u00e5det.<\/p>\n<p>Gruppen, som best\u00e5r av fyra externa medlemmar och ett antal medlemmar fr\u00e5n Nanexa, kommer identifiera relevanta indikationer och aktiva substanser som matchar viktiga medicinska behov inom onkologiomr\u00e5det d\u00e4r Nanexas drug delivery- plattform PharmaShell\u00ae erbjuder nya behandlingsf\u00f6rdelar. Rekommendationer fr\u00e5n denna grupp kommer tillsammans med marknadsdata f\u00f6r relevanta indikationer leda till beslut om produktprojekt baserat p\u00e5 PharmaShell\u00ae.<\/p>\n<p>De externa medlemmarna i Nanexas Advisory Board \u00e4r:<\/p>\n<p>Jan-Olof Fernberg, Docent i klinisk onkologi<br \/>Matthias L\u00f6hr, Professor och \u00f6verl\u00e4kare, Enheten f\u00f6r kirurgi, Karolinska Universitetssjukhuset<br \/>Bengt Westermark, Professor, Institutionen f\u00f6r immunologi, genetik och patologi, Uppsala universitet<br \/>Jeffrey Yachnin, Docent, Kliniska Pr\u00f6vningsenheten, Onkologiska kliniken, Karolinska Universitetssjukhuset<\/p>\n<p>F\u00f6r mer information kontakta:<br \/>David Westberg &#8211; VD, Nanexa AB (publ) Telefon: 0709 &#8211; 42 83 03<br \/>E-post: david.westberg@nanexa.se www.nanexa.com<\/p>\n<p>[image]<\/p>\n<p>Om Nanexa AB (publ)<\/p>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae har Nanexa samarbetsavtal med bland andra AstraZeneca.\u00a0<\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"http:\/\/mb.cision.com\/Main\/12591\/2436584\/781007.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa har identifierat onkologiomr\u00e5det som s\u00e4rskilt intressant och siktar p\u00e5 att under f\u00f6rsta halv\u00e5ret 2018 fatta ett inriktningsbeslut f\u00f6r ett eget produktprojekt inom omr\u00e5det. I syfte att staka ut v\u00e4gen f\u00f6r Nanexas egna produktprojekt har Bolaget samlat ett Advisory Board med djupa kunskaper inom onkologiomr\u00e5det.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3875","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa har identifierat onkologiomr\u00e5det som s\u00e4rskilt intressant och siktar p\u00e5 att under f\u00f6rsta halv\u00e5ret 2018 fatta ett inriktningsbeslut f\u00f6r ett eget produktprojekt inom omr\u00e5det. I syfte att staka ut v\u00e4gen f\u00f6r Nanexas egna produktprojekt har Bolaget samlat ett Advisory Board med djupa kunskaper inom onkologiomr\u00e5det.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-26T12:23:50+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/\",\"name\":\"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2018-01-23T11:07:11+00:00\",\"dateModified\":\"2020-06-26T12:23:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-forstarker-med-advisory-board-inom-onkologi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB","og_description":"Nanexa har identifierat onkologiomr\u00e5det som s\u00e4rskilt intressant och siktar p\u00e5 att under f\u00f6rsta halv\u00e5ret 2018 fatta ett inriktningsbeslut f\u00f6r ett eget produktprojekt inom omr\u00e5det. I syfte att staka ut v\u00e4gen f\u00f6r Nanexas egna produktprojekt har Bolaget samlat ett Advisory Board med djupa kunskaper inom onkologiomr\u00e5det.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","og_site_name":"Nanexa AB","article_modified_time":"2020-06-26T12:23:50+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/","name":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2018-01-23T11:07:11+00:00","dateModified":"2020-06-26T12:23:50+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-forstarker-med-advisory-board-inom-onkologi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa f\u00f6rst\u00e4rker med Advisory Board inom onkologi"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}